prikaz prve stranice dokumenta Melphalan modifies the bone microenvironment by enhancing osteoclast formation
  Preuzmi
PDF 10.05 MB
Znanstveni rad - Izvorni znanstveni rad
Melphalan modifies the bone microenvironment by enhancing osteoclast formation
Oncotarget, 8 (2017), 40; 68047-6858. https://doi.org/10.18632/oncotarget.19152
Chai, Ryan C.; McDonald, Michelle M.; Terry, Rachael L.; Kovačić, Nataša; Down, Jenny M.; Pettitt, Jessica A.; Mohanty, Sindhu T.; Shah, Shruti; Haffari, Gholamreza; Xu, Jiake; Gillespie, Matthew T.; Rogers, Michael J.; Price, John T.; Croucher, Peter I.; Quinn, Julian M.W. Više autora...

Citirajte ovaj rad

Chai, R. C., McDonald, M. M., Terry, R. L., Kovačić, N., Down, J. M., Pettitt, J. A. ... Quinn, J. M. (2017). Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget, 8. (40), 68047-6858. doi: 10.18632/oncotarget.19152

Chai, Ryan C., et al. "Melphalan modifies the bone microenvironment by enhancing osteoclast formation." Oncotarget, vol. 8, br. 40, 2017, str. 68047-6858. https://doi.org/10.18632/oncotarget.19152

Chai, Ryan C., Michelle M. McDonald, Rachael L. Terry, Nataša Kovačić, Jenny M. Down, Jessica A. Pettitt, Sindhu T. Mohanty, et al. "Melphalan modifies the bone microenvironment by enhancing osteoclast formation." Oncotarget 8, br. 40 (2017): 68047-6858. https://doi.org/10.18632/oncotarget.19152

Chai, R. C., et al. (2017) 'Melphalan modifies the bone microenvironment by enhancing osteoclast formation', Oncotarget, 8(40), str. 68047-6858. doi: 10.18632/oncotarget.19152

Chai RC, McDonald MM, Terry RL, Kovačić N, Down JM, Pettitt JA, i sur.. Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget [Internet]. 10.07.2017. [pristupljeno 05.05.2024.];8(40):68047-6858. doi: 10.18632/oncotarget.19152

R. C. Chai, et al., "Melphalan modifies the bone microenvironment by enhancing osteoclast formation", Oncotarget, vol. 8, br. 40, str. 68047-6858, Srpanj 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:798910. [Citirano: 05.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:798910
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Melphalan modifies the bone microenvironment by enhancing osteoclast formation
AutorRyan C. Chai
AutorMichelle M. McDonald
AutorRachael L. Terry
AutorNataša Kovačić
AutorJenny M. Down
AutorJessica A. Pettitt
AutorSindhu T. Mohanty
AutorShruti Shah
AutorGholamreza Haffari
AutorJiake Xu
AutorMatthew T. Gillespie
AutorMichael J. Rogers
AutorJohn T. Price
AutorPeter I. Croucher
AutorJulian M.W. Quinn
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Melphalan is a cytotoxic chemotherapy used to treat patients with multiple myeloma (MM). Bone resorption by osteoclasts, by remodeling the bone surface, can reactivate dormant MM cells held in the endosteal niche to promote tumor development. Dormant MM cells can be reactivated after melphalan treatment; however, it is unclear whether melphalan treatment increases osteoclast formation to modify the endosteal niche. Melphalan treatment of mice for 14 days decreased bone volume and the endosteal bone surface, and this was associated with increases in osteoclast numbers. Bone marrow cells (BMC) from melphalan-treated mice formed more osteoclasts than BMCs from vehicle-treated mice, suggesting that osteoclast progenitors were increased. Melphalan also increased osteoclast formation in BMCs and RAW264.7 cells in vitro, which was prevented with the cell stress response (CSR) inhibitor KNK437. Melphalan also increased expression of the osteoclast regulator the microphthalmia-associated transcription factor (MITF), but not nuclear factor of activated T cells 1 (NFATc1). Melphalan increased expression of MITF-dependent cell fusion factors, dendritic cell-specific transmembrane protein (Dc-stamp) and osteoclast-stimulatory transmembrane protein (Oc-stamp) and increased cell fusion. Expression of osteoclast stimulator receptor activator of NFκB ligand (RANKL) was unaffected by melphalan treatment. These data suggest that melphalan stimulates osteoclast formation by increasing osteoclast progenitor recruitment and differentiation in a CSR-dependent manner. Melphalan-induced osteoclast formation is associated with bone loss and reduced endosteal bone surface. As well as affecting bone structure this may contribute to dormant tumor cell activation, which has implications for how melphalan is used to treat patients with MM.
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaOncotarget
Brojčani podacivol. 8, br. 40, str. 68047-6858
p-ISSN1949-2553
DOIhttps://doi.org/10.18632/oncotarget.19152
URN:NBNurn:nbn:hr:105:798910
Datum objave publikacije2017-07-10
URL dokumentahttps://doi.org/10.18632/oncotarget.19152
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:15:42